Phase II study of cisplatin-combined schedules as second-line chemotherapy in patients with non-small cell lung cancer

Anticancer Research

Volumn 25, Issue 4, 2005, Pages 2991-2996

  Veslemes, Marinos ^a   Antoniou, Dimosthenis ^a   Georgatou, Niki ^a   Giamboudakis, Pantelis ^a   Dimitroulis, John ^a   Katis, Kostas ^b   Stathopoulos, George P ^b,c,d  

^a SOTIRIA GENERAL HOSPITAL   (Greece)

^b Errikos Dunant Hospital   (Greece)

^c SOLCA Study Group   (Greece)

^d NONE   (Greece)

Author keywords

Cisplatin combination; NSCLC

Indexed keywords

CARBOPLATIN; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; GEMCITABINE; NAVELBINE; ONDANSETRON; PACLITAXEL;

ADULT; AGED; ALLERGY; ANEMIA; ARTICLE; BONE MARROW TOXICITY; CANCER CONTROL; CARDIOTOXICITY; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOLOGY; CYTOTOXICITY; DIARRHEA; DISEASE COURSE; DRUG EFFICACY; DRUG RESPONSE; FATIGUE; FEMALE; HISTOLOGY; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SURVIVAL TIME; THROMBOCYTOPENIA; TUMOR GROWTH;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; DEOXYCYTIDINE; DEXAMETHASONE; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED;

EID: 22944471435     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Non-Small Cell Lung Cancer Collaborative Group: Chemotherapy in non-small-cell lung cancer, a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Br Med J 311: 899-909, 1995.
2. Cullen MH, Billingham LJ, Woodroffe CM, Chetyawardana AD, Gower NH, Joshi R et al: Mitomycin, ifosfamide and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 17: 3188-3194, 1999.
3. Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J et al: Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346: 92-98, 2002.
4. Pronzato P, Landucci M, Vaira F, Vigani A and Bertelli G: Failure of vinorelbine to produce responses in pretreated non-small-cell lung cancer patients. Anticancer Research 14: 1413-1415, 1994.
5. Hainsworth JD, Thomson DS and Greco FA: Paclitaxel by 1-hour infusion: an active drug in metastatic non-small-cell lung cancer. J Clin Oncol 13: 1609-1614, 1995.
6. Belani CP: Single agents in the second-line treatment of non-small-cell lung cancer. Semin Oncol 25: 10-14, 1998.
7. Crino L, Mosconi AM, Scagliotti GV, Selvaggi G, Rinaldi M, Dell GM et al: Gemcitabine as second-line treatment for relapsing or refractory advanced non-small-cell lung cancer: a phase II trial. Semin Oncol 25: 23-26, 1998.
8. Scullier JP, Lafitte JJ, Berghmans T, Thiriaux J, Licomte J, Efremidis A et al: A phase II trial testing gemcitabine as second-line chemotherapy for non-small-cell lung cancer. Lung Cancer 29: 67-73, 2000.
9. Scullier JP, Berghmans T, Lafitte JJ, Richez M, Recloux P, Van Cutsem O et al: A phase II study testing gemcitabine as second-line single agent treatment for patients with advanced non-small-cell lung cancer failing after a first-line chemotherapy. Lung Cancer 37: 73-77, 2002.
10. Laack E, Dierlamm T, Knuffmann C, Popp J, Scmied B, Durk H et al: Docetaxel and carboplatin as second-line chemotherapy for metastatic non-small-cell lung cancer. Lung Cancer 36: 303-307, 2002.
11. Fossella FV, Lynch T and Shepherd FA: Second-line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 38: 5-12, 2002.
12. Fossella FV, Lee JS, Shin DM, Calayag M, Huber M, Perez-Soler R et al: Phase II study of docetaxel for advanced or metastatic platinum-refractory non-small-cell lung cancer. J Clin Oncol 13: 645-651, 1995.
13. Gandara DR, Vokes E, Green M, Bonomi P, Devore R, Comis R et al: Activity of docetaxel in platinum-treated non-small-cell lung cancer: results of a phase II multicenter trial. J Clin Oncol 18: 131-135, 2000.
14. Robinet G, Thomas P, Perol M, Vergnenegre A, Lena H, Taytard A et al: Efficacy of docetaxel in non-small-cell lung cancer patients previously treated with platinum-containing chemotherapy. French Group of Pneumo-Cancerology. Rev Mal Respir 17: 83-89, 2000.
15. Kakolyris S, Kouroussis Ch, Souglakos J, Agelakis S, Kalbakis K, Vardakis N, Vamvakas L and Georgoulias V: Cisplatin and irinotecan (CPT-11) as second-line treatment in patients with advanced non-small-cell lung cancer. Lung Cancer 34: S71-S76, 2001.
16. Georgoulias V, Kouroussis Ch, Agelidou A, Boukovinas I, Palamidas P, Stavrinidis E, Polyzos A, Syrigos K, Veslemes M, Toubis M, Ardavanis A, Tselepatiotis and Vlachonikolis I, for the Lung Cancer Committee of the Hellenic Oncology Research Group (HORG): Irinotecan plus gemcitabine vs irinotecan for the second-line treatment of patients with advanced non-small-cell lung cancer pretreated with docetaxel and cisplatin: a multicenter, randomized phase II study. Br J Cancer 1-7, 2004. (in press)
17. Androulakis N, Kouroussis Ch, Kakolyris S, Tzannes S, Papadakis E, Souglakos J, Kotsakis A, Vardakis N, Hatzidaki D and Georgoulias V: Salvage treatment with paclitaxel and gemcitabine for patients with non-small-cell lung cancer after cisplatin- or docetaxel-based chemotherapy: a multicenter phase II study. Ann Oncol 9: 1127-1130, 1998.
18. Androulakis N, Papadakis E, Bania E, Apostolopoulou P, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Chainis K, Kouroussis Ch, Sarra E, Vardakis N, Hatzidaki D and Georgoulias V: Second-line treatment with docetaxel (D) and gemcitabine (G) in patients with advanced non-small-cell lung cancer (NSCLC): a multicenter phase II trial. Proc Ann Soc Clin Oncol 18: 494a, 1999.
19. Herrero CC, Martinez EN and Jaime AB: Second-line treatment with gemcitabine and vinorelbine in non-small-cell lung cancer cisplatin failures: a pilot study. Lung Cancer 27: 47-53, 2000.
20. Iaffaioli RV, Tortoriello A, Gravina A, Facchini G, Turitto G, Ella S, Griffo S, Gentile M, Praioli G, Frattolillo A, Muto P, Libutti M, De Marino V, Illiano A and Barbarisi A: Phase I-II study of gemcitabine and paclitaxel in pretreated patients with stage IIIb-IV non-small-cell lung cancer. Lung Cancer 30: 203-210, 2000.
21. Kosmas C, Tsavaris N, Panopoulos C, Vadiaka M, Stavroyianni N, Kourelis T, Malamos N, Antonopoulos M and Kalofonos HP: Gemcitabine and vinorelbine as second-line therapy in non-small-cell lung cancer after prior treatment with taxane+platinum-based regimens. Eur J Cancer. 37: 972-978, 2001.
22. Leu KM, Kim KM, Larson M and Schiller JH: Phase I/II of docetaxel and vinorelbine in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. Lung Cancer 34: 105-113, 2001.
23. Crino L, Mosconi AM, Scagliotti GV, Selvaggi G, Novell S, Rinaldi M, Della Giulia M, Gridelli C, Rossi A, Calandi C, De Marinis F, Noseda M and Tonato M: Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17: 2081-2085, 1999.
24. Fossella FV, De Vore R, Kerr RN, Crawford J, Natale RR, Dunphy F, Kalman L, Miller V, Lee JS, moore M, Candara D, Karp D, Vokes E, Kris M, Kim Y, Gamza F and Hammerahaimb L: Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 18: 2354-2362, 2000.
25. Shepherd FA, Fossella FV, Lynch T, Armand JP, Rigas JR and Kris MG: Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small-cell lung cancer: a review of phase III trials. Semin Oncol 28(1 Suppl 2): 4-9, 200.
26. Socinski MA, Steagall A and Gillenwater H: Second-line chemotherapy with 96 h infusional paclitaxel in refractory non-small-cell lung cancer: report of a phase II trial. Cancer Invest 17: 181-188, 1999.
27. Shepherd FA, Dancey J, Ramlau R, Mattson K, Gralla R, O'Rourke M, Levitan N, Gressot L, Vincent M, Burkes R, Coughlin S, Kim Y and Berille J. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18: 2095-2103, 2000.
28. Ferringo D and Buccheri G: Second-line chemotherapy for recurrent non-small-cell lung cancer: do new agents make a difference? Lung Cancer 29: 91-104, 2000.
29. Crino L, Mosconi AM, Scagliotti G et al: Gemcitabine as second-line treatment for advanced non-small-cell lung cancer: a phase II trial. J Clin Oncol 17: 2081-2085, 1999.
30. Huisman C, Smit EF, Giaccone G and Postmus PE: Second-line chemotherapy in relapsing or refractory non-small-cell lung cancer: a review. J Clin Oncol 18: 3722-3730, 2000.
31. Kakolyris S, Papadakis E, Tsiafaki X, Kalofonos C, Rapti A, Toubis M, Bania E, Kouroussis Ch, Chainis K, Androulakis N, Agelaki S, Sarra E, Vardakis N and Georgoulias V: Docetaxel in combination with gemcitabine plus rh G-CSF support as second-line treatment in non-small-cell lung cancer A multicenter phase II study. Lung Cancer 32: 179-187, 2001.
32. Buccheri G and Ferrigno D: Second-line weekly paclitaxel in patients with inoperable non-small-cell lung cancer who fail combination chemotherapy with cisplatin. Lung Cancer 45: 227-236, 2004.
33. Massarell E, Andre F, Liu DD, Lee JJ, Wolf M, Fandi A, Ochs J, Le Chevalier T, Fossella F and Herbst RS: A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39: 55-61, 2003.
34. Dancey J, Shepherd FA, Gralla R and Kim YS: Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial. Lung Cancer 43: 183-194, 2004.
35. Wachters FM, Van Putten JWG, Boezen HM and Groen HJM: Phase II study of docetaxel and carboplatin as second treatment in NSCLC. Lung Cancer 45: 255-262, 2004.
36. Georgoulias VA: Second-line chemotherapy in relapsing or refractory patients with non-small-cell lung cancer. Lung Cancer 38: 61-66, 2002
37. Kakolyris S, Souglakos J, Agelaki S, Kouroussis Ch, Mavroudis D, Sarra E, Malliotakis P and Georgoulias V: A dose-escalation study of irinotecan (CPT-II) in combination with cisplatin in patients with advanced non-small-cell lung cancer previously treated with a docetaxel-based front-line chemotherapy. Lung Cancer 30: 193-198, 2000.
38. De Pas T, de Braud F, Mandala M, Curigliano G, Catania C, Ferretti G, Sozzi P, Solli P and Goldhirsch A: Cisplatin and vinorelbine as second-line chemotherapy in patients with advanced non-small-cell lung cancer (NSCLC) resistant to taxol plus gemcitabine. Lung Cancer 31: 267-270, 2001.
39. Agelaki S, Bania H, Kouroussis Ch, Blazoyiannakis G, Souglakos J, Tsiafaki X, Kalbakis K, Rapti A, Androulakis N, Georgoulias V and Papadakis E: Second-line treatment with vinorelbine and carboplatin in patients with advanced non-small-cell lung cancer, A multicenter phase II study. Lung Cancer 34: 77-80, 2001.